You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The plan piggybacks on national influenza surveillance, testing flu-negative samples using the CDC's rRT-PCR test for the novel coronavirus.
A recent study established high sensitivity and specificity for three CLIA waived point-of-care molecular flu tests in pediatric samples.
A handful of rapid 2019-nCoV assays are in the works which could help triage patients more effectively and avoid unnecessary quarantines.
The Centers for Disease Control and Prevention says one of the test reagents will likely need to be remanufactured in its labs.
The agency is also hosting a portal for submissions and inquiries as part of the newly created Medical Countermeasures Taskforce.
A number of firms internationally have announced development of molecular assays and reagents for the novel coronavirus 2019-nCoV.
If granted, emergency use authorization is anticipated to help roll out standardized, consistent 2019-nCoV testing to public health labs in the US.
The system showed good performance for cervical samples as well as orophyrengeal samples, and required no extraction step.
The Ottawa-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.
The agency plans to make test kits available to state and international partners in the next two weeks. It also provided updated information about the virus.
An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.
The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.
CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.
In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.